If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
860
results.
Updated on
15/11/2026 [07:11:00]
Results 25 to 50 of 860
Absstract of: US20260345573A1
Described herein is an improved method of treatment with iloperidone or an active metabolite thereof, of a patient in need of such treatment, where such patient has a history of gout or is a carrier of a genetic variant associated with iloperidone-induced increases in serum urate concentration. The improved method comprises monitoring a serum urate level of the patient; and in an event that the serum urate level of the patient exceeds a reference level, initiating treatment with, or increasing a dose of a urate lowering treatment.
Absstract of: US20260345614A1
Compositions and methods are provided for determining protein biomarkers associated with periodic limb movements (PLMs) and/or restless legs syndrome (RLS) in an individual. These protein biomarkers are useful in patient identification and stratification, and also provide drug targets for therapeutic intervention. In some embodiments an individual is treated for PLM and/or RLS by administering a drug that acts on a protein target identified herein.
Absstract of: US20260348984A1
0000 Provided herein is a method for diagnosing and treating Alzheimer's disease comprising: (a) providing a biological sample obtained from the subject; (b) measuring concentration levels from the obtained sample, at least one, at least two, at least three, at least four or at least five Alzheimer's-related metabolites described herein and/or at least one, at least two, at least three, at least four or at least five Alzheimer's-related proteins described herein; (c) comparing the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample to the concentration levels of corresponding reference Alzheimer's-related metabolites and/or proteins from an Alzheimer's-negative sample; (d) identifying the subject as having Alzheimer's if the concentration levels of the Alzheimer's-related metabolites and/or proteins from the obtained sample are different relative to the concentration levels of the reference Alzheimer's-related metabolites and/or proteins from the Alzheimer's-negative sample; and (e) treating or causing treatment of the subject.
Absstract of: US20260348980A1
Stroke is the second cause of death and the first cause of adult disability in industrialized countries. The goal of emergency therapy for acute ischemic stroke is prompt restoration of blood flow to regions of brain that are ischemic but not yet infarcted. Based on this, the inventors compare the plasma concentration of total tPA (antigenic: active+PAI-1 bound) in patients with acute ischemic stroke before any treatment with those in a healthy control group, to evaluate the interest of tPA as a potential diagnostic biomarker in the acute phase of ischemic stroke. In particular, the present invention relates to method for discriminating at early stage an hemorrhagic stroke from an ischemic stroke or a mimic stroke in a subject in need thereof, comprising the steps of i) determining in a blood sample obtained from the said subject the level of tissue-type plasminogen activator (tPA), ii) comparing the level determined in step i) with a reference value and iii) concluding when the level of tissue-type plasminogen activator (tPA) determined at step i) is higher than the reference value is predictive of a risk of having or developing an ischemic stroke or a mimic stroke or concluding when the level of tissue-type plasminogen activator (tPA) determined at step i) is lower than the reference value is predictive of a risk of having or developing a hemorrhagic stroke
Absstract of: US20260347465A1
Provided herein are antibodies, including antigen-binding fragments thereof, that bind all or a portion thereof of CEA-CAM6, compositions containing such antibodies or antigen-binding fragments thereof, combinations of such antibodies or antigen-binding fragments thereof and methods of use. In particular embodiments, the antibodies or antigen-binding fragments thereof are used in methods of detecting the presence of CEACAM6 through imaging, including molecular, medical and diagnostic imaging.
Absstract of: US20260345531A1
0000 A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.
Absstract of: US20260348985A1
0000 Provided herein are methods of obtaining and applying measurements of metabolites to diagnosing ASD in a subject, particularly children, with high specificity and sensitivity. The metabolites can be measured in urine, serum, and whole blood samples.
Absstract of: US20260345011A1
0000 A method for measuring a physiological parameter of a user with a physiological measurement device. The physiological measurement device is applied to tissue of the user and causing light to be emitted from a light source physically incorporated into the housing. Performing an analysis of a first reflected light signal, a second reflected light signal, and a first ambient light signal. Based on the performed analysis, generating a processed output signal having a signal-to-noise ratio that is greater than a signal-to-noise ratio of the first reflected light signal, the processed output signal being associated with the physiological parameter of the user. Determining a measurement of the physiological parameter for the user using the processed output signal.
Absstract of: US20260347849A1
0000 The present invention provides iRNA agents, e.g., double stranded iRNA agents, that target the transthyretin (TTR) gene and methods of using such iRNA agents for treating or preventing TTR-associated diseases.
Absstract of: US20260348949A1
0000 The present invention describes compositions for use in a proximity assay for detecting glycosylated molecules in a sample, and methods of use of the compositions for a proximity assay for detecting glycosylated molecules.
Absstract of: US20260348976A1
The present invention relates to antibodies or binding fragments thereof for use in methods of identifying or diagnosing diseases associated with extracellular trap formation or release from cells, such as Neutrophil Extracellular Trap (NET)-associated pathologies or Eosinophil Extracellular Trap (EET)-associated pathologies.
Absstract of: EP4835470A2
Provided herein is a dual cell aggregate culture of retinal epithelial cells and photoreceptors for use as a research tool, such as the screening of compounds or model for study of retinal diseases, as well as a therapeutic for treating ocular diseases.
Absstract of: WO2025068372A1
The invention relates to a microfluidic device (12) for depositing a sample of a body fluid onto a sensor element (26) in order to detect biomarkers and/or condition a sensor element (26) for a biomarker detection. The invention additionally relates to a biomarker detection device (10) comprising the microfluidic device (12). The invention likewise relates to a method for depositing a sample onto a sensor element (26) in order to detect biomarkers and/or condition a sensor element (26) for a biomarker detection and to a method for analyzing biomarkers in a sample (212).
Absstract of: WO2025068424A1
The invention relates to: a microfluidic device (12) for applying a sample to a sensor element (26) for biomarker detection; and a biomarker detection device (10) comprising the microfluidic device (12). The invention also relates to: a method for applying a sample to a sensor element (26) for biomarker detection; and a method for detecting biomarkers in a bodily fluid, for example for analysing protein defects in a blood sample (212).
Absstract of: WO2025076292A1
The present invention relates to a NLRP3 variant comprising at least a partial deletion of the PYD. The present invention further relates to a method of screening for a compound that inhibits the NLRP3 inflammasome. The present invention further provides a method comprising the step of administering a compound identified by such a screening method to a subject with a NLRP3-associated inflammatory disorder.
Absstract of: WO2025085755A1
Disclosed are methods of detecting or quantifying a pathology -related or pathology-protective-pathway in a subject comprising combining a first ligand with a sample obtained from the subject comprising an extracellular particle, wherein the first ligand binds to a cell-type specific marker on the extracellular particle; combining a second ligand with the sample, wherein the second ligand binds to a pathology-related or pathology-protective pathway molecule on the extracellular particle; combining a donor bead to the sample, wherein the donor bead binds to the first ligand or second ligand; combining an acceptor bead to the sample, wherein the acceptor bead binds to the first ligand or second ligand, wherein the donor bead and acceptor bead do not bind to the same ligand; triggering the donor bead to activate the acceptor bead to produce a signal; wherein the amount, presence, or absence of a signal indicates the amount, presence, or absence of a pathological condition in the subject.
Absstract of: US20260335295A1
A compound represented by Formula 1, a stereoisomer thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically acceptable salt thereof according to one aspect can be utilized as a preventive or therapeutic agent and the like for degenerative diseases, such as macular degeneration (AMD), cerebral amyloid angiopathy, hereditary stroke (CADASIL), and Alzheimer's disease (AD), in which HTRA1 activity deficiency is a factor in the aggravation of the diseases, and can be utilized as an adjuvant for efficiently and accurately performing screening of an HTRA activity modulator without temperature changes or the addition of substrates.
Absstract of: WO2025078596A1
The present invention provides a non-invasive, ex vivo method for diagnosing, prognosing or monitoring Parkinson's disease (PD) in a subject, the method comprising determining the ratio of CD8 terminally- differentiated effector T cells (CD8 TEMRA) to CD8 central memory T cells (CD8 TCM) in a biological sample from the subject, and computer program products for carrying out the method. Also provided herein is a kit, in particular a kit for diagnosing, prognosing or monitoring PD, the kit comprising: (a) means specifically adapted for determining the ratio of CD8 TEMRA to CD8 TCM; and (b) optionally a reference for said ratio or means for establishing said reference, wherein said reference represents a known diagnosis or prognosis of PD, wherein (a) and optionally (b) are the only biological reagents present in said kit, and uses thereof.
Absstract of: US20260338774A1
0000 Disclosed herein are methods of detecting citrullinated polypeptides and/or citrullinated peptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in various body fluids and/or tissues of individuals with autoimmune diseases, for example the synovium of subjects with rheumatoid arthritis. Further disclosed are methods of diagnosing, treating, selecting an individual for treatment of, and monitoring the treatment of autoimmune diseases, such as rheumatoid arthritis or hidradenitis suppurativa. Kits for use with the methods described herein are also provided.
Absstract of: US20260337661A1
The present disclosure provides compositions and methods useful in modulating integrated stress response (ISR) and associated diseases or disorders and methods of identifying ISR modulators. The present disclosure also provides methods of treating neurodegenerative conditions and predicting beneficial effects and identifying suitable targets for treatment.
Absstract of: AU2026249053A1
A method for detecting p217+tau in blood-based samples from a subject with high 5 sensitivity, accuracy, and precision. The assay comprises contacting a sample with a capture antibody directed against a p217+tau epitope to bind the capture antibody to p217+tau peptides in plasma to form antibody-peptide complexes, and separately contacting the antibody-peptide complexes with a detection antibody to bind the detection antibody to the antibody-peptide complexes. The amount of p217+tau is determined by detecting the detection antibody. The 10 amount of p217+tau detected is used to determine whether the subject has tauopathy or is at risk of developing tauopathy, or whether the subject has amyloidogenic disease or is at risk of developing amyloidogenic disease when the amount of p217+tau peptides is above a predetermined threshold value. The method has improved sensitivity such that the predetermined threshold value is above a Lower Limit of Quantification and/or Lower Limit of Detection of the 15 assay. ct c t
Absstract of: US20260335402A1
The present invention relates to compositions and methods for promoting the removal of misfolded proteins and protein aggregates. The compositions and methods may be used to treat or prevent a neurodegenerative disease or disorder associated with misfolded proteins or protein aggregates. In various embodiments, the compositions and methods relate to activators of one or more TRIM proteins.
Absstract of: AU2026249014A1
A method of processing a biological sample in a microfluidic cartridge by generating a target analyte, binding the analyte to magnetic particles, actuating a plunger mechanism to pressurise reagent pouches and dispense reagents into interconnected reagent wells and a primary fluidic conduit to establish a fluidic circuit, and sequentially magnetically transporting the analyte-bound magnetic particles through the fluidic circuit from one reagent well to the next for assay processing. On-chip burst pouch106 Empty reaction chamber Rocker Cam 102 Filled reaction chamber Cam 102 Filled reaction chamber ct c t i l l e d r e a c t i o n c h a m b e r
Absstract of: US20260338764A1
The present invention relates to a method of profiling the energetic metabolism of a single cells. The inventors designed a method that rapidly and efficiently measures the protein synthesis level in single cells upon inhibition of the different energy producing pathways. The method developed by the inventors permits to acquire energetic metabolism profiles with single cell resolution in non-abundant cells ex-vivo and permits to decrease to a minimum manipulation time, incubations and cost of sample preparation. The method is particularly suitable for determining activation state of a cell, diagnosing inflammatory diseases, or predicting the response of a subject to immunotherapy treatment. In particular, the present invention relates to a method of profiling the energetic metabolism in single cells comprising measuring the protein synthesis level of the cells and contacting the cell with different inhibitors of metabolic pathways.
Nº publicación: WO2026223261A1 29/10/2026
Applicant:
UNIV SOUTH CHINA NORMAL [CN]
\u534E\u5357\u5E08\u8303\u5927\u5B66
Absstract of: WO2026223261A1
The present application discloses a three-dimensional bipolar ECL-based lateral flow immunoassay strip and a use thereof in immunoassay. The three-dimensional bipolar ECL-based lateral flow immunoassay strip comprises a three-dimensional bipolar electrode sheet, a lateral flow immunoassay strip, and a connecting pad; the three-dimensional bipolar electrode sheet is arranged at the lower side, and the lateral flow immunoassay strip and the connecting pad are arranged at the upper side; the three-dimensional bipolar electrode sheet is of a layered structure, and comprises a first electrode sheet layer and a second electrode sheet layer; the second electrode sheet layer is arranged at the lower side, and the first electrode sheet layer is arranged at the upper side; the second electrode sheet layer comprises a positive driving electrode; the positive driving electrode comprises a positive driving electrode head end, a positive driving electrode tail end, and a connecting wire thereof. The present invention designs the three-dimensional bipolar electrode sheet for the first time, and the electrode sheet comprises the first electrode sheet layer and the second electrode sheet layer that are bonded together by means of an adhesive backing. This design overcomes the defects of traditional bipolar ECL electrode sheets, and is more suitable for the requirements of rapid on-site detection.
BOPI
Electronic site
